{
    "name": "pralsetinib",
    "comment": "Rx",
    "other_names": [
        "Gavreto"
    ],
    "classes": [
        "RET Kinase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/gavreto-pralsetinib-4000124",
    "pregnancy": {
        "common": [
            "Based on animal studies and its mechanism of action, fetal harm may occur when administered to pregnant females",
            "No data available on use in pregnant females to inform drug-associated risk",
            "Verify pregnancy status of females of reproductive potential before initiation"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective nonhormonal contraception during treatment and for 2 weeks after final dose; pralsetinib may render hormonal contraceptives ineffective",
                    "Males with female partners of reproductive potential: Use effective contraception during treatment and for 1 week after final dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on histopathological findings in male and female rats and a dedicated fertility study, fertility may be impaired"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Oral pralsetinib administered to pregnant rats during organogenesis resulted in malformation and embryolethality at maternal exposures below human exposure at a dose of 400 mg qDay",
                    "Advise pregnant females of potential risk to fetus"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of pralsetinib or its metabolites in human milk, effects on breastfed children, or on milk production",
            "Advise females not to breastfeed during treatment and for 1 week after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Severe, life-threatening, and fatal ILD/pneumonitis can occur; monitor for pulmonary symptoms indicative of ILD/pneumonitis",
                "Serious hepatic adverse reactions reported; monitor AST/ALT before initiation, every 2 weeks during first 2 months, and then monthly thereafter and as clinically indicated",
                "May cause serious, including fatal, hemorrhagic events",
                "Based on findings from animal studies and its mechanism of action, may cause fetal harm when administered to pregnant females",
                "Tumor lysis syndrome reported in MTC-treated patients; patients may be at risk of TLS if they have rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration; closely monitor patients at risk, consider appropriate prophylaxis including hydration, and treat as clinically indicated"
            ],
            "specific": [
                {
                    "type": "Hypertension",
                    "description": [
                        "Hypertension occurred; treatment-emergent hypertension was mostly managed with antihypertensive therapy",
                        "Do not initiate with uncontrolled hypertension",
                        "Optimize blood pressure (BP) before initiation",
                        "Monitor BP after 1 week, then at least monthly thereafter and as clinically indicated",
                        "Initiate or adjust antihypertensive therapy as needed"
                    ]
                },
                {
                    "type": "Impaired wound healing",
                    "description": [
                        "Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway",
                        "May have potential to adversely affect wound healing",
                        "Withhold for at least 5 days prior to elective surgery",
                        "Do not administer for at least 2 weeks following major surgery and until adequate wound healing",
                        "Safety of resumption after resolution of wound healing complications has not been established"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Pralsetinib is a CYP3A4 and P-gp substrate",
                        "Strong CYP3A4 inhibitors ",
                        "Avoid coadministration",
                        "Strong CYP3A inhibitors increase exposure and risk of toxicities to pralsetinib",
                        "Combined P-gp and strong CYP3A inhibitors ",
                        "Avoid coadministration; if unable to avoid, decrease pralsetinib dose",
                        "Combined P-gp and strong CYP3A inhibitors increase plasma concentrations and effects of pralsetinib",
                        "Strong CYP3A4 inducers",
                        "Avoid coadministration; if unable to avoid, increase pralsetinib dose",
                        "Strong CYP3A inducers decrease exposure to pralsetinib"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of pralsetinib by  affecting hepatic enzyme CYP2E1 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit will increase the level or effect of pralsetinib by  Other (see comment). Avoid or Use Alternate Drug. Combined CYP3A4 and P-gp inhibitors increase levels of pralsetinib, a CYP3A4 and P-gp substrate. If unable to avoid, reduce dose (see pralsetinib prescribing information). After combined P-gp and strong CYP3A4 inhibitor discontinued, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of pralsetinib by  affecting hepatic enzyme CYP2E1 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid use with drugs that are both strong CYP3A4 and P-gp inhibitors when possible. If combined, reduce pralsetinib dose to 200 mg qDay (if current dose is 300-400 mg qDay) or 100 mg qDay ( if current dose is 200 mg qDay) After CYP3A4 and P-gp inhibitor has been discontinued for 3-5 elimination half-lives, resume pralsetinib at the dose taken before initiating the inhibitor."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid use with drugs that are both strong CYP3A4 and P-gp inhibitors when possible. If combined, reduce pralsetinib dose to 200 mg qDay (if current dose is 300-400 mg qDay) or 100 mg qDay ( if current dose is 200 mg qDay) After CYP3A4 and P-gp inhibitor has been discontinued for 3-5 elimination half-lives, resume pralsetinib at the dose taken before initiating the inhibitor."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "lumacaftor/ivacaftor will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of pralsetinib by  Other (see comment). Avoid or Use Alternate Drug. Combined CYP3A4 and P-gp inhibitors increase levels of pralsetinib, a CYP3A4 and P-gp substrate. If unable to avoid, reduce dose (see pralsetinib prescribing information). After combined P-gp and strong CYP3A4 inhibitor discontinued, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotorasib",
            "description": {
                "common": "sotorasib will decrease the level or effect of pralsetinib by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer. After inducer has been discontinued for at least 14 days, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol increases toxicity of pralsetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tepotinib",
            "description": {
                "common": "tepotinib will increase the level or effect of pralsetinib by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If concomitant use unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of pralsetinib by  Other (see comment). Avoid or Use Alternate Drug. Combined CYP3A4 and P-gp inhibitors increase levels of pralsetinib, a CYP3A4 and P-gp substrate. If unable to avoid, reduce dose (see pralsetinib prescribing information). After combined P-gp and strong CYP3A4 inhibitor discontinued, resume previous pralsetinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "berotralstat",
            "description": {
                "common": "berotralstat will increase the level or effect of pralsetinib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor or titrate P-gp substrate dose if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "lonafarnib will increase the level or effect of pralsetinib by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Lonafarnib is a weak P-gp inhibitor. Monitor for adverse reactions if coadministered with P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicities. Reduce P-gp substrate dose if needed."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "NSCLC  Increased AST",
            "percent": "69"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "54"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "52"
        },
        {
            "name": "Decreased neutrophils",
            "percent": "52"
        },
        {
            "name": "Increased ALT",
            "percent": "46"
        },
        {
            "name": "Increased creatinine",
            "percent": "42"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "40"
        },
        {
            "name": "Constipation",
            "percent": "35"
        },
        {
            "name": "Fatigue",
            "percent": "35"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "32"
        },
        {
            "name": "Decreased calcium",
            "percent": "29"
        },
        {
            "name": "corrected",
            "percent": "28"
        },
        {
            "name": "Hypertension",
            "percent": "27"
        },
        {
            "name": "Decreased sodium",
            "percent": "27"
        },
        {
            "name": "Decreased phosphate",
            "percent": "26"
        },
        {
            "name": "Decreased platelets",
            "percent": "24"
        },
        {
            "name": "Diarrhea",
            "percent": "23"
        },
        {
            "name": "Cough",
            "percent": "20"
        },
        {
            "name": "Pyrexia",
            "percent": "20"
        },
        {
            "name": "Edema",
            "percent": "17"
        },
        {
            "name": "Pneumonia",
            "percent": "16"
        },
        {
            "name": "Dry mouth",
            "percent": "69"
        },
        {
            "name": "Increased AST",
            "percent": "54"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "52"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "52"
        },
        {
            "name": "Decreased neutrophils",
            "percent": "46"
        },
        {
            "name": "Increased ALT",
            "percent": "42"
        },
        {
            "name": "Increased creatinine",
            "percent": "40"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "35"
        },
        {
            "name": "Constipation",
            "percent": "35"
        },
        {
            "name": "Fatigue",
            "percent": "32"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "29"
        },
        {
            "name": "Decreased calcium",
            "percent": "28"
        },
        {
            "name": "corrected",
            "percent": "27"
        },
        {
            "name": "Hypertension",
            "percent": "27"
        },
        {
            "name": "Decreased sodium",
            "percent": "26"
        },
        {
            "name": "Decreased phosphate",
            "percent": "24"
        },
        {
            "name": "Decreased platelets",
            "percent": "23"
        },
        {
            "name": "Diarrhea",
            "percent": "20"
        },
        {
            "name": "Cough",
            "percent": "20"
        },
        {
            "name": "Pyrexia",
            "percent": "17"
        },
        {
            "name": "Edema",
            "percent": "16"
        },
        {
            "name": "Pneumonia",
            "percent": "70"
        },
        {
            "name": "Dry mouth",
            "percent": "69"
        },
        {
            "name": "Thyroid cancer Decreased calcium",
            "percent": "67"
        },
        {
            "name": "corrected",
            "percent": "63"
        },
        {
            "name": "Increased AST",
            "percent": "59"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "43"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "42"
        },
        {
            "name": "Decreased neutrophils",
            "percent": "41"
        },
        {
            "name": "Increased ALT",
            "percent": "41"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "41"
        },
        {
            "name": "Constipation",
            "percent": "40"
        },
        {
            "name": "Increased creatinine",
            "percent": "40"
        },
        {
            "name": "Decreased albumin",
            "percent": "38"
        },
        {
            "name": "Hypertension",
            "percent": "34"
        },
        {
            "name": "Increased phosphate",
            "percent": "31"
        },
        {
            "name": "Fatigue",
            "percent": "29"
        },
        {
            "name": "Diarrhea",
            "percent": "28"
        },
        {
            "name": "Decreased platelets",
            "percent": "28"
        },
        {
            "name": "Edema",
            "percent": "27"
        },
        {
            "name": "Decreased sodium",
            "percent": "27"
        },
        {
            "name": "Decreased phosphate",
            "percent": "27"
        },
        {
            "name": "Cough",
            "percent": "26"
        },
        {
            "name": "Decreased magnesium",
            "percent": "24"
        },
        {
            "name": "Decreased magnesium",
            "percent": "24"
        },
        {
            "name": "Increased potassium",
            "percent": "24"
        },
        {
            "name": "Headache",
            "percent": "22"
        },
        {
            "name": "Rash",
            "percent": "22"
        },
        {
            "name": "Increased bilirubin",
            "percent": "22"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "20"
        },
        {
            "name": "Dyspnea",
            "percent": "19"
        },
        {
            "name": "Pyrexia",
            "percent": "17"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "17"
        },
        {
            "name": "Dizziness",
            "percent": "17"
        },
        {
            "name": "Dysgeusia",
            "percent": "17"
        },
        {
            "name": "Abdominal pain",
            "percent": "17"
        },
        {
            "name": "Dry mouth",
            "percent": "15"
        },
        {
            "name": "Stomatitis",
            "percent": "15"
        },
        {
            "name": "Nausea",
            "percent": "15"
        },
        {
            "name": "Decreased appetite",
            "percent": "70"
        },
        {
            "name": "Tumor lysis syndrome",
            "percent": "69"
        },
        {
            "name": "Increased creatinine phosphokinase",
            "percent": "67"
        },
        {
            "name": "Decreased calcium",
            "percent": "63"
        },
        {
            "name": "corrected",
            "percent": "59"
        },
        {
            "name": "Increased AST",
            "percent": "43"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "42"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "41"
        },
        {
            "name": "Decreased neutrophils",
            "percent": "41"
        },
        {
            "name": "Increased ALT",
            "percent": "41"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "40"
        },
        {
            "name": "Constipation",
            "percent": "40"
        },
        {
            "name": "Increased creatinine",
            "percent": "38"
        },
        {
            "name": "Decreased albumin",
            "percent": "34"
        },
        {
            "name": "Hypertension",
            "percent": "31"
        },
        {
            "name": "Increased phosphate",
            "percent": "29"
        },
        {
            "name": "Fatigue",
            "percent": "28"
        },
        {
            "name": "Diarrhea",
            "percent": "28"
        },
        {
            "name": "Decreased platelets",
            "percent": "27"
        },
        {
            "name": "Edema",
            "percent": "27"
        },
        {
            "name": "Decreased sodium",
            "percent": "27"
        },
        {
            "name": "Decreased phosphate",
            "percent": "26"
        },
        {
            "name": "Cough",
            "percent": "24"
        },
        {
            "name": "Decreased magnesium",
            "percent": "24"
        },
        {
            "name": "Decreased magnesium",
            "percent": "24"
        },
        {
            "name": "Increased potassium",
            "percent": "22"
        },
        {
            "name": "Headache",
            "percent": "22"
        },
        {
            "name": "Rash",
            "percent": "22"
        },
        {
            "name": "Increased bilirubin",
            "percent": "20"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "19"
        },
        {
            "name": "Dyspnea",
            "percent": "17"
        },
        {
            "name": "Pyrexia",
            "percent": "17"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "17"
        },
        {
            "name": "Dizziness",
            "percent": "17"
        },
        {
            "name": "Dysgeusia",
            "percent": "17"
        },
        {
            "name": "Abdominal pain",
            "percent": "15"
        },
        {
            "name": "Dry mouth",
            "percent": "15"
        },
        {
            "name": "Stomatitis",
            "percent": "15"
        },
        {
            "name": "Nausea",
            "percent": "20"
        },
        {
            "name": "Decreased appetite",
            "percent": "14"
        },
        {
            "name": "Tumor lysis syndrome",
            "percent": "20"
        },
        {
            "name": "Increased creatinine phosphokinase",
            "percent": "14"
        },
        {
            "name": "NSCLC Decreased lymphocytes",
            "percent": "27"
        },
        {
            "name": "Hypertension",
            "percent": "21"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "16"
        },
        {
            "name": "Hypertension",
            "percent": "13"
        },
        {
            "name": "Thyroid cancer Decreased lymphocytes",
            "percent": "27"
        },
        {
            "name": "Hypertension",
            "percent": "21"
        },
        {
            "name": "Decreased neutrophils",
            "percent": "16"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "13"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "10"
        },
        {
            "name": "Hypertension",
            "percent": "10"
        },
        {
            "name": "Decreased neutrophils",
            "percent": "10"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "10"
        },
        {
            "name": "NSCLC Hyperphosphatemia",
            "percent": "10"
        },
        {
            "name": "Pneumonitis",
            "percent": "9"
        },
        {
            "name": "Hyperphosphatemia",
            "percent": "8"
        },
        {
            "name": "Pneumonitis",
            "percent": "5"
        },
        {
            "name": "NSCLC Decreased neutrophils",
            "percent": "3.2"
        },
        {
            "name": "Decreased phosphate",
            "percent": "3.2"
        },
        {
            "name": "Pneumonia",
            "percent": "2.7"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "2.3"
        },
        {
            "name": "Decreased sodium",
            "percent": "2.2"
        },
        {
            "name": "Diarrhea",
            "percent": "2.1"
        },
        {
            "name": "Pneumonitis",
            "percent": "2"
        },
        {
            "name": "Fatigue",
            "percent": "1.1"
        },
        {
            "name": "Decreased calcium",
            "percent": "1.1"
        },
        {
            "name": "corrected",
            "percent": "1.1"
        },
        {
            "name": "Increased ALT",
            "percent": "1"
        },
        {
            "name": "Sepsis",
            "percent": "10"
        },
        {
            "name": "Increased AST",
            "percent": "9"
        },
        {
            "name": "Increased creatinine",
            "percent": "8"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "5"
        },
        {
            "name": "Constipation",
            "percent": "3.2"
        },
        {
            "name": "Decreased neutrophils",
            "percent": "3.2"
        },
        {
            "name": "Decreased phosphate",
            "percent": "2.7"
        },
        {
            "name": "Pneumonia",
            "percent": "2.3"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "2.2"
        },
        {
            "name": "Decreased sodium",
            "percent": "2.1"
        },
        {
            "name": "Diarrhea",
            "percent": "2"
        },
        {
            "name": "Pneumonitis",
            "percent": "1.1"
        },
        {
            "name": "Fatigue",
            "percent": "1.1"
        },
        {
            "name": "Decreased calcium",
            "percent": "1.1"
        },
        {
            "name": "corrected",
            "percent": "1"
        },
        {
            "name": "Increased ALT",
            "percent": "8"
        },
        {
            "name": "Sepsis",
            "percent": "6"
        },
        {
            "name": "Increased AST",
            "percent": "5"
        },
        {
            "name": "Increased creatinine",
            "percent": "4.3"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "3.6"
        },
        {
            "name": "Constipation",
            "percent": "2.9"
        },
        {
            "name": "Thyroid cancer Decreased phosphate",
            "percent": "2.2"
        },
        {
            "name": "Fatigue",
            "percent": "2.2"
        },
        {
            "name": "Diarrhea",
            "percent": "2.2"
        },
        {
            "name": "Increased AST",
            "percent": "1.5"
        },
        {
            "name": "Increased ALT",
            "percent": "1.4"
        },
        {
            "name": "Decreased platelets",
            "percent": "1.4"
        },
        {
            "name": "Pyrexia",
            "percent": "1.4"
        },
        {
            "name": "Dyspnea",
            "percent": "1.4"
        },
        {
            "name": "Decreased sodium",
            "percent": "8"
        },
        {
            "name": "Decreased albumin",
            "percent": "6"
        },
        {
            "name": "Cough",
            "percent": "5"
        },
        {
            "name": "Increased potassium",
            "percent": "4.3"
        },
        {
            "name": "Increased bilirubin",
            "percent": "3.6"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "2.9"
        },
        {
            "name": "Decreased phosphate",
            "percent": "2.2"
        },
        {
            "name": "Fatigue",
            "percent": "2.2"
        },
        {
            "name": "Diarrhea",
            "percent": "2.2"
        },
        {
            "name": "Increased AST",
            "percent": "1.5"
        },
        {
            "name": "Increased ALT",
            "percent": "1.4"
        },
        {
            "name": "Decreased platelets",
            "percent": "1.4"
        },
        {
            "name": "Pyrexia",
            "percent": "1.4"
        },
        {
            "name": "Dyspnea",
            "percent": "1.4"
        },
        {
            "name": "Decreased sodium",
            "percent": "0.5"
        },
        {
            "name": "Decreased albumin",
            "percent": "0.5"
        },
        {
            "name": "Cough",
            "percent": "0.7"
        },
        {
            "name": "Increased potassium",
            "percent": "0.7"
        },
        {
            "name": "Increased bilirubin",
            "percent": "0.7"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "0.7"
        },
        {
            "name": "NSCLC Cough",
            "percent": "0.7"
        },
        {
            "name": "Cough",
            "percent": "0.7"
        },
        {
            "name": "Thyroid cancer Musculoskeletal pain",
            "percent": "0.7"
        },
        {
            "name": "Constipation",
            "percent": "0.7"
        },
        {
            "name": "Abdominal pain",
            "percent": "0.7"
        },
        {
            "name": "Stomatitis",
            "percent": "0.7"
        },
        {
            "name": "Nausea",
            "percent": "0.7"
        },
        {
            "name": "Dizziness",
            "percent": "0.7"
        },
        {
            "name": "Decreased magnesium",
            "percent": "0.7"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "0.7"
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Stomatitis",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Decreased magnesium",
            "percent": null
        }
    ]
}